The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir
- PMID: 27936974
- DOI: 10.1080/17474124.2017.1270205
The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir
Abstract
Without treatment, many of the 200 million people worldwide with chronic hepatitis C virus (HCV) infection will develop cirrhosis or liver cancer. Japan was the first nation to approve an interferon-free therapy for HCV, and sustained viral response (SVR) rates >90% have been achieved with asunaprevir, a protease inhibitor, plus daclatasvir, an inhibitor of the non-structural 5A (NS5A) protein. Areas covered: This review provides an overview of the results from both clinical trials and real world experience with asunaprevir and daclatasvir therapy focused primarily on Japan. A literature search using the keywords 'asunaprevir,' 'daclatasvir,' 'interferon-free therapy,' and 'direct-acting antiviral drugs' was initially used to select relevant literature for inclusion in the review. Expert commentary: While not approved in the United States, dual therapy with asunaprevir plus daclatasvir has already been successfully used in Japan and throughout East Asia to treat many thousands of patients. Pre-existing or treatment-emergent NS5A-Y93 or -L31 resistance-associated variants (RAVs) may lead to viral breakthrough, and alternative therapies should be considered for these patients, but patients who harbor NS5A RAVs only at low frequency are likely to achieve SVR. The therapy has also been shown to be safe and effective with renal dysfunction or liver cirrhosis.
Keywords: Direct-acting antiviral agents; NS5A inhibitor; interferon-free therapy; polymerase inhibitor; protease inhibitor; resistance-associated variants; sustained virological response.
Similar articles
-
Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.J Med Virol. 2015 Nov;87(11):1913-20. doi: 10.1002/jmv.24255. Epub 2015 Jun 16. J Med Virol. 2015. PMID: 25954851 Clinical Trial.
-
Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.J Gastroenterol. 2017 Apr;52(4):504-511. doi: 10.1007/s00535-016-1255-4. Epub 2016 Sep 8. J Gastroenterol. 2017. PMID: 27631593 Clinical Trial.
-
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.J Gastroenterol Hepatol. 2016 Nov;31(11):1860-1867. doi: 10.1111/jgh.13379. J Gastroenterol Hepatol. 2016. PMID: 27003037 Clinical Trial.
-
Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.Aliment Pharmacol Ther. 2015 Aug;42(3):258-72. doi: 10.1111/apt.13264. Epub 2015 May 27. Aliment Pharmacol Ther. 2015. PMID: 26014906 Review.
-
Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection.Drugs Today (Barc). 2015 Nov;51(11):629-43. doi: 10.1358/dot.2015.51.11.2414528. Drugs Today (Barc). 2015. PMID: 26744738 Review.
Cited by
-
Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.J Gastroenterol. 2018 Jun;53(6):780-786. doi: 10.1007/s00535-017-1405-3. Epub 2017 Nov 1. J Gastroenterol. 2018. PMID: 29094205
-
Decline incidence in upper gastrointestinal bleeding in several recent years: data of the Japan claims database of 13 million accumulated patients.J Clin Biochem Nutr. 2021 Jan;68(1):95-100. doi: 10.3164/jcbn.20-153. Epub 2020 Dec 3. J Clin Biochem Nutr. 2021. PMID: 33536718 Free PMC article.
-
HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.PLoS One. 2017 Dec 7;12(12):e0187409. doi: 10.1371/journal.pone.0187409. eCollection 2017. PLoS One. 2017. PMID: 29216198 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources